Neurocrine Biosciences
NBIX
$166.80
-10.08%
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. It is a commercial-stage biotechnology company with a strong presence in CNS and rare diseases, anchored by its flagship product Ingrezza for tardive dyskinesia and a growing pipeline. The current investor narrative centers on the company's acquisition of Soleno Therapeutics to tap the high-growth rare disease market, which has pressured the stock near-term but is viewed as a strategic long-term catalyst. Additionally, analysts remain bullish despite conservative 2026 Ingrezza guidance, seeing the sell-off as a buying opportunity.…
NBIX
Neurocrine Biosciences
$166.80
Related headlines
NBIX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Neurocrine Biosciences's 12-month outlook, with a consensus price target around $202.39 and implied upside of +21.3% versus the current price.
Average Target
$202.39
0 analysts
Implied Upside
+21.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$170 - $251
Analyst target range
Neurocrine is covered by 27 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.43 on a 1-5 scale). The average price target is $202.17, implying approximately 15% upside from the current price of $175.77. The distribution leans heavily bullish, with no sell ratings and only a few hold ratings, reflecting strong conviction in the company's growth story. The target range spans from $170.00 (low) to $250.65 (high). The high target of $250.65 implies 43% upside and likely assumes successful integration of Soleno, continued Ingrezza growth, and pipeline success. The low target of $170.00 is slightly below the current price, suggesting some analysts see limited downside but also limited near-term catalysts. Recent ratings from major firms (Truist, RBC, JP Morgan, Citigroup) have all been bullish, with no downgrades, indicating sustained positive sentiment. The wide spread between low and high targets ($80.65) reflects high uncertainty around pipeline and acquisition outcomes, but the overall bullish consensus suggests the market expects positive developments.
Drowning in data?
Find the real signal!
Bulls vs Bears: NBIX Investment Factors
Neurocrine Biosciences presents a compelling growth story with accelerating revenue (42.3% YoY), expanding margins (net margin 24.3%), and strong free cash flow ($831M TTM). The bull case is supported by a bullish analyst consensus (Strong Buy, 15% upside to average target) and low volatility (beta 0.39). However, bears point to a premium valuation (trailing P/E 29.5x vs. industry 22x), single-product concentration, and integration risks from the Soleno acquisition. The single most important tension is whether the company can sustain its high growth trajectory and successfully integrate Soleno to justify its premium valuation. Currently, the bull case has stronger evidence given the accelerating revenue and strong profitability, but the stock's near-term performance hinges on execution of the acquisition and Ingrezza growth.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 42.3% YoY to $814.5M, accelerating from 22.5% in Q4 2025 and 29.5% in Q3 2025, indicating strong commercial momentum for Ingrezza and other products.
- Strong Profitability and Margins: Net margin expanded to 24.3% in Q1 2026 from 15.6% a year earlier, with gross margin at 98.3% and operating margin at 22.8%, demonstrating operating leverage as revenue scales.
- Robust Free Cash Flow Generation: Free cash flow TTM is $831.3M, providing ample internal funding for growth initiatives and the Soleno acquisition without excessive leverage.
- Bullish Analyst Consensus: 27 analysts rate the stock a Strong Buy (mean 1.43/5) with an average target of $202.17, implying 15% upside. No sell ratings and a high target of $250.65 suggest significant upside potential.
Bearish
- Premium Valuation vs. Peers: Trailing P/E of 29.5x is 34% above the biotech industry average of 22x, leaving limited margin of safety if growth disappoints.
- Soleno Acquisition Integration Risk: The acquisition of Soleno Therapeutics for rare disease drugs adds pipeline potential but near-term execution risk and stock pressure, as seen in the 10.6% drop on conservative Ingrezza guidance.
- Conservative Ingrezza Guidance: Disappointing 2026 Ingrezza guidance triggered a sharp sell-off in February 2026, highlighting sensitivity to product-specific forecasts and potential market saturation.
- High Short Interest: Short ratio of 4.48 days to cover indicates elevated bearish sentiment, which could amplify downside if negative news emerges.
NBIX Technical Analysis
Neurocrine Biosciences is in a sustained uptrend, with the stock up 33.5% over the past year, significantly outperforming the S&P 500's 16.5% gain. The current price of $175.77 sits at 97% of its 52-week range (52-week low: $122.14, high: $181.18), indicating strong momentum and positioning near the top of the range, which suggests bullish sentiment but also potential overextension. Short-term momentum is accelerating: the stock has gained 5.8% in the past month and 37.7% over the past three months, both outpacing the S&P 500's 0.8% and 3.5% returns, respectively. This consistent outperformance across time frames confirms a robust uptrend with no signs of divergence. The 52-week high of $181.18 acts as immediate resistance; a breakout above this level would signal further upside and confirm the continuation of the uptrend. Support lies near the 52-week low of $122.14, though the stock is well above that level. With a beta of 0.39, the stock is significantly less volatile than the market, meaning it offers a smoother ride for investors but may lag during sharp market rallies.
Beta
—
—
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$122-$186
Price range past year
Annual Return
+30.1%
Cumulative gain past year
| Period | NBIX Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | +0.2% |
| 3m | +26.6% | +3.7% |
| 6m | +22.6% | +8.0% |
| 1y | +30.1% | +18.2% |
| ytd | +18.6% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NBIX Fundamental Analysis
Revenue growth is accelerating strongly: Q1 2026 revenue of $814.5 million grew 42.3% year-over-year, up from 22.5% YoY growth in Q4 2025 ($805.5 million) and 29.5% in Q3 2025 ($794.9 million). The growth is driven by product sales of $811 million, with collaboration revenue contributing only $3.5 million, indicating the company's commercial engine is firing on all cylinders. This accelerating top-line trend supports a bullish investment case, as it suggests increasing market penetration and demand for its therapies. Profitability is solid and improving: net income in Q1 2026 was $197.9 million, up from $107.5 million in Q2 2025, with a net margin of 24.3% compared to 15.6% a year earlier. Gross margin remains exceptionally high at 98.3%, typical for biotech with low cost of goods sold. Operating margin expanded to 22.8% from 21.2% in Q2 2025, reflecting operating leverage as revenue scales. The balance sheet is strong: debt-to-equity is only 0.13, and the current ratio is 3.39, indicating ample liquidity. Free cash flow TTM is $831.3 million, providing significant internal funding for growth and acquisitions. ROE of 14.7% demonstrates efficient capital use, and the company has no dividend, reinvesting all earnings into growth.
Quarterly Revenue
$814500000.0B
2026-03
Revenue YoY Growth
+42.3%
YoY Comparison
Gross Margin
98.3%
Latest Quarter
Free Cash Flow
$831300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NBIX Overvalued?
Since net income is positive ($197.9 million in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 29.5x, while the forward P/E is 13.9x, implying the market expects significant earnings growth in the coming year. The large gap between trailing and forward P/E suggests the market is pricing in robust future earnings expansion, likely driven by the Soleno acquisition and pipeline progress. Compared to the biotechnology industry average P/E of approximately 22x (based on sector data), Neurocrine's trailing P/E of 29.5x represents a 34% premium. However, this premium is justified by the company's superior revenue growth (42.3% YoY) and high net margins (24.3%), which are well above industry norms. Historically, the stock's trailing P/E has ranged from 16.7x (Q1 2026) to 345.6x (Q1 2025) over the past two years. The current 29.5x is near the lower end of that range, suggesting the stock is not overvalued relative to its own history, especially considering the accelerating growth trajectory.
PE
29.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~100x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Neurocrine's balance sheet is strong with a debt-to-equity ratio of only 0.13 and current ratio of 3.39, but the company faces operational risk from its heavy reliance on Ingrezza, which generated over 99% of product sales in Q1 2026. Any setback in Ingrezza's market position or pricing could significantly impact revenue. Additionally, the Soleno acquisition adds integration risk and near-term dilution, as evidenced by the 10.6% stock drop on conservative guidance. Free cash flow of $831M TTM provides a cushion, but the forward P/E of 13.9x implies high earnings growth expectations that leave little room for error.
Market & Competitive Risks: The stock's trailing P/E of 29.5x is a 34% premium to the biotech industry average of 22x, making it vulnerable to valuation compression if growth slows. With a beta of 0.39, the stock is less sensitive to broad market moves, but sector rotation away from growth or negative regulatory news could still pressure shares. The short ratio of 4.48 days indicates elevated bearish sentiment, and the wide analyst target range ($170-$250.65) reflects high uncertainty around pipeline and acquisition outcomes. Recent news highlights the Soleno acquisition as a strategic move, but near-term execution risk remains.
Worst-Case Scenario: In a severe downturn, if Ingrezza faces unexpected competition or the Soleno integration fails, the stock could fall to its 52-week low of $122.14, representing a 30.5% decline from the current price of $175.77. This scenario would likely involve multiple analyst downgrades and a reassessment of growth prospects. The historical max drawdown of -20.9% provides a reference, but given the premium valuation and single-product risk, a deeper correction is possible.
